NCT07947043
Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
ORR
Timeframe: Up to 12 months after first dose
Secondary (3)
PFS
DOR
OS
Arms and interventions
Autologous Tumor-Infiltrating Lymphocyte InjectionExperimental
Autologous Tumor-Infiltrating Lymphocyte Injection with a single administration dose of 1×10¹⁰ (±20%), 3×10¹⁰ (±20%), and 5×10¹⁰ (±20%) cells per person per administration respectively.
Biologicals: Autologous Tumor-Infiltrating Lymphocyte Injection
Sites
1 site in 1 country
- Tongji HospitalWuhan, Hubei, China